Bear no matter what, the MACE lowering is what gave Amarin the big boost in their Market Cap.

I can't see Amarin's 25% statistical significance in MACE would change from here on end. Why would it?   

Lowering triglyceride, with the only benefit, leaves Amarin a $3 stock. I guess the takeaway here is that lower MACE is more critical than lowering triglyceride. Hard to believe. If so that bodes well potentially, for Apabeatlone should it succeed.

Koo